Shots: The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop NK cell and T cell-engaging Abs and Genentech will take care of all global clinical development and commercialization Affimed to receive an upfront $96M and […]Read More
